| 前收盘价格 | 25.15 |
| 收盘价格 | 24.95 |
| 成交量 | 27,336,595 |
| 平均成交量 (3个月) | 55,952,239 |
| 市值 | 104,361,639,936 |
| 市盈率 (P/E TTM) | 30.18 |
| 预期市盈率 (P/E Forward) | 24.27 |
| 价格/销量 (P/S) | 5.21 |
| 股市价格/股市净资产 (P/B) | 2.24 |
| 52周波幅 | |
| 利润日期 | 19 Aug 2025 - 25 Aug 2025 |
| 营业毛利率 | 17.97% |
| 营业利益率 (TTM) | 27.38% |
| 稀释每股收益 (EPS TTM) | 0.850 |
| 季度收入增长率 (YOY) | 18.30% |
| 季度盈利增长率 (YOY) | 63.90% |
| 总债务/股东权益 (D/E MRQ) | 10.86% |
| 流动比率 (MRQ) | 2.73 |
| 营业现金流 (OCF TTM) | 5.22 B |
| 杠杆自由现金流 (LFCF TTM) | -2.30 B |
| 资产报酬率 (ROA TTM) | 5.05% |
| 股东权益报酬率 (ROE TTM) | 8.82% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (HK) | 混合的 | 混合的 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | WUXI BIO | - | - |
AIStockmoo 评分
-1.0
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 0.5 |
| 平均 | -1.00 |
相关股票
| 股票 | 市值 | DY | P/E（TTM） | P/B |
|---|---|---|---|---|
| WUXI BIO | 104 B | - | 30.18 | 2.24 |
| SINO BIOPHARM | 102 B | 1.26% | 51.73 | 2.65 |
| PHARMARON | 47 B | 1.23% | 15.04 | 1.88 |
| INNOVENT BIO | 126 B | - | - | 8.83 |
| AKESO | 88 B | - | - | 11.02 |
| BEIGENE | 221 B | - | - | 8.31 |
|
WuXi Biologics is one of the largest global biologic global contract development and manufacturing organizations. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 18.7 billion. North America represented 57.3% of total revenue in 2024. The firm has a "follow and win the molecule" strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual sourcing strategy by providing drug products and drug substance manufacturing. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Large Core |
| 内部持股比例 | 13.07% |
| 机构持股比例 | 35.41% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合